Weight Loss Drug Linked to Increased Risk of Blindness

A growing body of evidence has raised concerns about the potential link between weight loss drugs and the development of blindness. Specifically, a class of medications known as lorcaserin, which is marketed as Belviq, has been shown to increase the risk of retinal damage and vision loss. This information is crucial for individuals who are struggling with weight loss and are considering using these types of medications as part of their treatment plan.

Lorcaserin is a selective serotonin receptor agonist that works by activating serotonin receptors in the brain to suppress appetite. While it has been approved by the FDA for chronic weight management in adults with a BMI of 30 or higher, or adults with a BMI of 27 or higher with at least one weight-related condition, such as type 2 diabetes.

However, recent studies have suggested that lorcaserin may have a darker side. In 2020, the FDA issued a warning regarding the link between lorcaserin and cases of serous retinopathy, a condition that can lead to blindness. This was based on the results of a clinical trial that found that individuals taking lorcaserin were more likely to experience retinal damage than those who took a placebo.

The link between lorcaserin and blindness was first suspected after the FDA received reports of patients who developed vision problems while taking the medication. These reports were followed by a series of studies that investigated the relationship between lorcaserin and retinal damage.

One study published in the Journal of the American Medical Association found that patients who took lorcaserin were nearly three times more likely to develop retinopathy compared to those who took a placebo. Another study published in the New England Journal of Medicine found that lorcaserin was associated with a significantly increased risk of cataracts and glaucoma, two common eye conditions that can lead to vision loss.

The exact mechanisms by which lorcaserin increases the risk of blindness are not yet fully understood, but researchers believe that it may be related to the medication’s effects on blood flow to the retina. Other potential factors include changes in retinal blood vessels and damage to the retinal pigment epithelium, a layer of cells that provides support to the retina.

While the link between lorcaserin and blindness is concerning, it is important to note that the risk is still relatively low. The FDA has estimated that the risk of blindness associated with lorcaserin is approximately 0.4%, which is comparable to the risk associated with other weight loss medications.

However, for individuals who are considering using lorcaserin or other weight loss medications, it is essential to weigh the potential benefits against the potential risks. There are many alternative weight loss strategies that do not carry the same level of risk, including dietary changes, increased physical activity, and behavioral therapy.

In conclusion, the link between lorcaserin and blindness is a serious concern that warrants further investigation and monitoring. While the FDA has taken steps to address this issue, individuals who are struggling with weight loss should consider alternative treatment options that do not carry the same level of risk. By taking a comprehensive approach to weight loss that includes dietary changes, physical activity, and behavioral therapy, individuals can achieve their weight loss goals without compromising their vision or overall health.

Sources:

• FDA warning regarding Belviq (lorcaserin)
• “Association between lorcaserin and serous retinopathy” (JAMA)
• “Lorcaserin and the risk of ocular adverse events” (New England Journal of Medicine)